m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03808)
Name
TP-1454
Status
Phase 1
TTD Drug ID
DLN0P8
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Pyruvate kinase M2 (PKM)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Pyruvate kinase M2 (PKM) is a therapeutic target for TP-1454. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of TP-1454 through regulating the expression of Pyruvate kinase M2 (PKM). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Pyruvate kinase M2 (PKM) is a therapeutic target for TP-1454. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TP-1454 through regulating the expression of Pyruvate kinase M2 (PKM). [2], [3]
Zinc finger CCCH domain-containing protein 13 (ZC3H13)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Pyruvate kinase M2 (PKM) is a therapeutic target for TP-1454. The Zinc finger CCCH domain-containing protein 13 (ZC3H13) has potential in affecting the response of TP-1454 through regulating the expression of Pyruvate kinase M2 (PKM). [2], [4]
References
Ref 1 m6A demethylase FTO promotes hepatocellular carcinoma tumorigenesis via mediating PKM2 demethylation. Am J Transl Res. 2019 Sep 15;11(9):6084-6092. eCollection 2019.
Ref 2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 3 YTHDF1 upregulation mediates hypoxia-dependent breast cancer growth and metastasis through regulating PKM2 to affect glycolysis. Cell Death Dis. 2022 Mar 23;13(3):258. doi: 10.1038/s41419-022-04711-1.
Ref 4 ZC3H13 Inhibits the Progression of Hepatocellular Carcinoma through m(6)A-PKM2-Mediated Glycolysis and Enhances Chemosensitivity. J Oncol. 2021 Dec 30;2021:1328444. doi: 10.1155/2021/1328444. eCollection 2021.